2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings. The author explores the data around their post-IPO share performance, relative to prior years.
Category: NASDAQ:NBI
The Rising Tide Of Biotech IPO Valuations
To frame up how the Biotech IPO markets have evolved over the past six years, the author reviews data around the changes to pre-money valuations over time. The trend line is clear: up and to the right
The Incredible Expanding Universe of Biotech Stocks
The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint.
